Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a SPOTLIGHT Clinical Study of Briquilimab in Chronic Inducible Urticaria
March 19, 2024
New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia
March 15, 2024
Jasper Therapeutics Reports Fiscal 2023 Financial Results and Recent Corporate Developments
March 4, 2024
Jasper Therapeutics to Present at the 43rd Annual TD Cowen Healthcare Conference
February 26, 2024
Jasper Therapeutics Presents Data from Preclinical Briquilimab Studies at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
February 23, 2024
Jasper Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Conference
February 7, 2024
Jasper Therapeutics Announces Pricing of $50 Million Underwritten Offering of Common Stock
February 6, 2024
Jasper Therapeutics Announces Preclinical Data Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
February 5, 2024
Jasper Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 2, 2024
Jasper Therapeutics Highlights Recent Accomplishments and Key Upcoming Milestones
January 5, 2024
Displaying 11 - 20 of 21